


Flash Report
-2Q Results and FY11 Outlook-

Teijin Limited
November 1, 2011

Outline of FY11 2Q Results

(1) Consolidated Results Highlights

(¥bn)



◆ Operating Results

(¥bn)	FY10 1H	FY11 1H	Diff.
Net sales	399.9	393.6	-6.3
OP	20.5	20.7	+0.1
OP margin	5.1%	5.2%	-
Nonoperating items (net)	(0.0)	1.0	+1.0
Ordinary income	20.5	21.7	+1.2
Extraordinary items (net)	(1.3)	(2.0)	-0.6
Income before income taxes	19.2	19.7	+0.5
Income taxes	6.9	9.4	+2.5
Minority interest in income	0.8	1.2	+0.4
Net income	11.5	9.2	-2.4
EPS (¥)	11.74	9.33	-2.40

EBITDA *1	48.5	43.8	-4.7
CAPEX *2	11.7	12.9	+1.2
Depreciation & amortization	28.0	23.2	-4.8
R&D expenses	15.3	15.2	-0.2
FCF	8.3	(16.6)	-24.9

*1 EBITDA = Operating income + Depreciation & amortization

*2 CAPEX includes investments in intangible assets

➤ Net sales and operating income: Essentially level with FY10 1H, reflecting:

- A decline in sales and operating income in the Films and Plastics segment, owing to the impact of the earthquake, together with stagnating demand for electronics equipment
- Firm sales and operating income in the High-Performance Fibers and the Polyester Fibers segments

➤ Ordinary income: Up, reflecting better results at unconsolidated affiliates accounted for by the equity method

➤ Net income: Down, owing to increase in income taxes resulting from an adjustment of deferred income taxes

◇ PL exchange rate

	FY10 1H	FY11 1H
¥/US\$	91	82
¥/€	121	115
US\$/€	1.33	1.40

Note: 1H for overseas companies is Jan.1 to June 30.

◆ Financial Position

(¥bn)	Mar. 31, '11	Sep. 30, '11	Diff.	(Impact of foreign exchange rate)
Total assets	761.5	784.5	+23.0	+7.0
Shareholders' equity	284.2	290.1	+5.8	+1.6
Interest-bearing debt	267.4	288.0	+20.6	+3.4

D/E ratio	0.94	0.99	+0.05
Shareholders' equity ratio	37.3%	37.0%	-0.3%

➤ Total assets: Up

- Increase in inventories

➤ Shareholders' equity: Up

- Owing to quarterly net income
- Despite decline in valuation difference on available-for-sale securities

➤ Interest-bearing debt: Up

- Attributable to increase in working capital

◆ Cash Flows





(¥bn)	Operating activities	Investing activities	FCF	Financing activities	Cash & cash equivalents
FY11 1H	1.6	-18.3	-16.6	14.5	-2.1
FY10 1H	21.1	-12.8	8.3	-5.6	2.7

◇ BS exchange rate

	Dec. 31, '10	June. 30, '11
¥/US\$	81	81
¥/€	108	117
US\$/€	1.32	1.45

Note: 1H for overseas companies is Jan.1 to June 30.


◆ Analysis of Changes in Operating Results and Financial Position



(2) Operating Results by Segment (Comparison with FY10 1H)

(¥bn)	Sales				OP			
	FY10 1H	FY11 1H	Diff.	% Change	FY10 1H	FY11 1H	Diff.	% Change
High-Performance Fibers	52.1	54.4	+2.3	+4.4%	1.2	4.2	+3.1	+265.1%
Polyester Fibers	50.9	53.9	+3.1	+6.0%	(0.0)	2.0	+2.0	-
Films & Plastics	110.8	93.0	-17.9	-16.1%	10.9	5.7	-5.2	-47.7%
Pharma. & H.H.C.	66.5	68.0	+1.6	+2.4%	11.8	11.9	+0.1	+0.9%
Trading & Retail	102.2	105.4	+3.2	+3.1%	1.9	2.4	+0.4	+22.9%
Total	382.5	374.7	-7.8	-2.0%	25.8	26.2	+0.4	+1.6%
Others	17.4	18.9	+1.5	+8.6%	0.9	1.1	+0.2	+21.0%
Elimination & corporate	-	-	-	-	(6.2)	(6.7)	-0.5	-
Total	399.9	393.6	-6.3	-1.6%	20.5	20.7	+0.1	+0.7%

① High-Performance Fibers: Increase in sales and operating income



(¥bn)	10/1H	11/1H	Diff.	Change
Sales	52.1	54.4	+2.3	+4.4%
OP	1.2	4.2	+3.1	+265.1%

◆ Summary & Actions


◇ Aramid Fibers:

- Para-aramid fibers: Demand was robust from all industries
- Meta-aramid fibers: Demand was firm for use in protective clothing
- Pushed ahead with efforts to cultivate new applications

◇ Carbon Fibers and Composites:

- Demand was brisk for use in aircraft
- Demand was solid for use in natural energy industries, as well as in civil engineering
- Demand for use in pressure vessels was hampered by the economic downturn in Europe
- In Asia, sales for use in compounds and in sports and leisure equipment were sluggish
- Actively marketed new thermoplastic CFRP to the automotive industry

② Polyester Fibers: Increase in sales, return to profitability




(¥bn)	10/1H	11/1H	Diff.	Change
Sales	50.9	53.9	+3.1	+6.0%
OP	(0.0)	2.0	+2.0	-

◆ Summary & Actions

◇ Polyester Fibers:

- Profit structure continued to improve steadily, thanks to the shift of production of certain products overseas
- Demand for automotive applications flagged in the immediate aftermath of the earthquake, but rallied sharply from the summer forward
- Sales were robust due to efforts to capitalize on demand associated with official energy saving initiatives and measures to promote cooler business attire, as well as on demand for materials for civil engineering and construction applications related to post-quake reconstruction

③ Films and Plastics: Decline in sales and operating income



(¥bn)	10/1H	11/1H	Diff.	Change
Sales	110.8	93.0	-17.9	-16.1%
OP	10.9	5.7	-5.2	-47.7%

◆ Summary & Actions


◇ Plastics:

- Polycarbonate resin:
 - Sales volume declined, owing to the impact of the earthquake, together with stagnating demand for use in LCD televisions, computers and other electronics equipment
 - Raw materials prices remained high
- Processed polycarbonate resin products:
 - Sales of polycarbonate retardation film for use in 3D glasses for movie theaters were sluggish

◇ Films:

- Demand was robust in the first half (Jan. to June) for use as FPD reflective film and in solar cell back sheets, but softened toward the end of the second quarter
- Forced to suspend production at two facilities following earthquake (resumed production at the Ibaraki Factory at the end of March 2011 and at the Utsunomiya Factory in mid-June)

④ Pharmaceuticals & Home Health Care: Increase in sales, slight increase in operating income



(¥bn)	10/1H	11/1H	Diff.	Change
Sales	66.5	68.0	+1.6	+2.4%
OP	11.8	11.9	+0.1	+0.9%

◆ Summary & Actions


◇ Pharmaceuticals:

- Japan: Sales of new drugs continued to expand favorably
 - *FEBURIC* (treatment for hyperuricemia and gout)
 - *Synvisc Dispo 2ml* (intra-articular injection-form drug for treating pain associated with osteoarthritis of the knee)
- Sales of osteoporosis treatment *Bonalon* were steady
- Overseas: Expanded geographical scale of marketing efforts for hyperuricemia treatment
 - Launched in ROK in July 2011
 - Signed exclusive distributorship agreements for Mexico, Middle East and North Africa, India, Southeast Asia and others

◇ Home Health Care:

- HOT: Rental volume remained firm
- CPAP/SAFHS: Rental volume continued to climb
- Overseas: Took steps to expand rental volume and reinforce earnings base

⑤ Trading and Retail: Increase in sales and operating income



(¥bn)	10/1H	11/1H	Diff.	Change
Sales	102.2	105.4	+3.2	+3.1%
OP	1.9	2.4	+0.4	+22.9%

◆ Summary & Actions

◇ Trading and Retail:

- **Textiles and Apparel**
 - Sales of sportswear, everyday apparel and men's suits rose, reflecting efforts to expand our mainstay OEM apparel business
 - Profit structure improved gradually, augmented by steps taken to reduce costs through greater production efficiency and the integration of production facilities
- **Industrial Textiles and Materials**
 - Sales of products for automotive-related applications flagged early in the first half, owing to the earthquake, but demand rallied toward the end of the period
 - Sales of industrial fabrics, nonwoven materials, filters and materials for civil engineering and fisheries-related applications were firm
 - Sales of heat-insulating films rose, bolstered by demand related to efforts to reduce energy consumption

◆ Changes in Net Sales and Operating Income for FY10-FY11

		FY10			FY11		
		1Q	2Q	1H	1Q	2Q	1H
		(¥bn)					
Net Sales	High-Performance Fibers	25.6	26.5	52.1	26.9	27.5	54.4
	Polyester Fibers	24.7	26.2	50.9	23.8	30.2	53.9
	Films & Plastics	51.8	59.1	110.8	46.9	46.1	93.0
	Pharma. & H.H.C.	33.7	32.8	66.5	34.9	33.1	68.0
	Trading & Retail	48.7	53.5	102.2	48.2	57.2	105.4
	Total	184.5	198.0	382.5	180.6	194.1	374.7
	Others	8.1	9.3	17.4	9.0	9.9	18.9
	Total	192.6	207.3	399.9	189.6	204.0	393.6
Operating Income	High-Performance Fibers	0.0	1.1	1.2	2.0	2.2	4.2
	Polyester Fibers	0.0	(0.0)	(0.0)	0.5	1.5	2.0
	Films & Plastics	3.6	7.3	10.9	3.2	2.6	5.7
	Pharma. & H.H.C.	6.9	4.9	11.8	7.2	4.7	11.9
	Trading & Retail	0.7	1.2	1.9	1.0	1.3	2.4
	Total	11.3	14.6	25.8	13.9	12.3	26.2
	Others	(0.1)	1.0	0.9	0.3	0.8	1.1
	Elimination & corporate	(3.1)	(3.1)	(6.2)	(3.2)	(3.5)	(6.7)
Total	8.1	12.4	20.5	11.0	9.6	20.7	




Outlook for FY11

2. Outlook for FY11


(1) Assessment of the operating environment

- The European sovereign debt and financial crises have triggered a global economic slowdown
- Economic growth in the PRC—until recently the principal driving force behind the global economy—has slowed as a consequence of monetary restraint
- Despite having largely recovered from the impact of the Great East Japan Earthquake, the Japanese economy continues to be hampered by a record-high yen, which impedes the profitability of exports

- Results remain firm in the Pharmaceuticals and Home Health Care segment, bolstered by favorable sales of new drugs, and in the aramid fibers business, owing to robust demand
- As a consequence of flagging demand from and prolonged inventory adjustments by manufacturers of LCD televisions, computers and solar cells, the Films and Plastics segment is on a downward swing
- Our polyester fibers subsidiaries in Thailand have had to suspend operations temporarily as a result of the recent severe flooding



(2) Movement of Results



(3) Summary of Outlook for FY11

	(¥bn)	FY10	FY11 Outlook	Difference		FY11 Previous Outlook* ²	Difference (Amount)
				Amount	%		
Net sales		815.7	890.0	+74.3	+9.1%	920.0	-30.0
Operating income		48.6	50.0	+1.4	+3.0%	61.0	-11.0
Operating margin		6.0%	5.6%	-	-0.3%	6.6%	-
Ordinary income		50.3	50.0	-0.3	-0.7%	61.0	-11.0
Net income		25.2	24.0	-1.2	-4.7%	32.0	-8.0
CAPEX * ¹		29.2	45.0	+15.8	+53.9%	45.0	0.0
Depreciation & amortization		56.4	55.0	-1.4	-2.5%	55.0	0.0
R&D expenses		31.5	33.0	+1.5	+4.8%	33.0	0.0

*1 CAPEX includes investments in intangible assets

◆ Forecast for Fiscal 2011(Yen/share)

No change from previous outlook*²


Interim	3.0
Year-end	3.0
Annual dividends	6.0

◆ Exchange rate and Crude Oil Price Forecast for FY11

	FY11 Previous Outlook* ²	FY11 Current Outlook
JPY per USD	81	79
JPY per EUR	115	111
Dubai crude oil price	US\$109/barrel	US\$109/barrel

*2 Announced on August 1, 2011

(4) Impact of Flooding on Thai Operations




Company name	Location	Main business	Current status
Teijin Cord (Thailand) Co., Ltd. (TCT)	Rojana Industrial Park in Ayutthaya Province	Manufacture and sales of core materials used in the carcasses of transmission belts for production machinery	Operation suspended on Oct. 8
Teijin (Thailand) Limited (TJT)	Bang Pa-in Industrial Estate in Ayutthaya Province	Manufacture and sales of polyester filament yarn and staple fiber	Operation suspended on Oct. 12
Teijin Polyester (Thailand) Limited (TPL)	Pathum Thani Province	Manufacture and sales of polyester filament yarn, staple fiber and industrial fiber	Operation suspended on Oct. 16
Thai Namsiri Intertex Co., Ltd. (TNI)	Textile plant: Wellgrow Industrial Estate in Chachoengsao Province Dyeing plant: Samut Prakan Province	Manufacture and sales of polyester textile	Operating normally

(5) Impact of severe flooding in Thailand

		Estimated impact on FY11 results
Operating income	Loss of earnings due to suspension of operations at Teijin Group's and customers' facilities	– ¥1.0 billion
	Increase in costs resulting from need to shift production to alternate sites	
Extraordinary loss	Cost to restore damaged facilities, net of insurance settlements	Not reflected in current forecasts

- The estimated impact on full-term fiscal 2011 operating income is as of the date of our results announcement for the first half. Depending on the time required before production facilities can resume operations, and other factors, this figure may change
- We will formulate an estimate for extraordinary loss once entry into the damaged facilities becomes possible



Should it be determined that results will diverge from our current forecasts, we will release new forecasts as soon as possible

(6) Outlook by Segment

		FY11 Previous Outlook *1					FY11 Revised Outlook *2				
		1H	2H	Sub-total	Additional period	Total	1H	2H	Sub-total	Additional period	Total
(¥bn)											
Net Sales	High-Performance Fibers	55.0	65.0	120.0	20.0	140.0	54.4	55.6	110.0	20.0	130.0
	Polyester Fibers	55.0	55.0	110.0	10.0	120.0	53.9	56.1	110.0	10.0	120.0
	Films & Plastics	95.0	110.0	205.0	40.0	245.0	93.0	97.0	190.0	35.0	225.0
	Pharma. & H.H.C.	70.0	75.0	145.0	5.0	150.0	68.0	77.0	145.0	5.0	150.0
	Trading & Retail	100.0	120.0	220.0	5.0	225.0	105.4	114.6	220.0	5.0	225.0
	Total	375.0	425.0	800.0	80.0	880.0	374.7	400.3	775.0	75.0	850.0
	Others	20.0	20.0	40.0	0.0	40.0	18.9	21.1	40.0	0.0	40.0
Total	395.0	445.0	840.0	80.0	920.0	393.6	421.4	815.0	75.0	890.0	
Operating Income	High-Performance Fibers	5.0	5.5	10.5	3.5	14.0	4.2	3.8	8.0	3.5	11.5
	Polyester Fibers	1.5	2.0	3.5	0.5	4.0	2.0	1.5	3.5	0.0	3.5
	Films & Plastics	6.5	10.5	17.0	3.0	20.0	5.7	4.8	10.5	2.0	12.5
	Pharma. & H.H.C.	12.5	15.5	28.0	0.0	28.0	11.9	16.1	28.0	0.0	28.0
	Trading & Retail	2.0	3.0	5.0	0.0	5.0	2.4	2.6	5.0	0.0	5.0
	Total	27.5	36.5	64.0	7.0	71.0	26.2	28.8	55.0	5.5	60.5
	Others	1.0	2.0	3.0	0.0	3.0	1.1	2.0	3.0	0.0	3.0
Elimination & corporate	(6.5)	(6.5)	(13.0)	0.0	(13.0)	(6.7)	(6.9)	(13.5)	0.0	(13.5)	
Total	22.0	32.0	54.0	7.0	61.0	20.7	23.8	44.5	5.5	50.0	


*1 Announced on August 1, 2011

*2 Announced on November 1, 2011

(7) Factors behind revision of operating income forecast

- Owing to a deterioration of market conditions, sales volume is expected to decline, particularly in the Films and Plastics segment
- Forecasts incorporate an estimate of the impact of flooding in Thailand on our business, based on information currently available
- We are stepping up short-term efforts to reduce costs

Breakdown of revision of operating income forecast



(8) Financial Highlights

	FY07 Actual	FY08 Actual	FY09 Actual	FY10 Actual	FY11 Outlook
ROA *1	6.5%	1.9%	1.6%	6.1%	6.6%
ROE *2	3.3%	(12.3%)	(12.4%)	9.1%	8.2%
Operating margin	6.3%	1.9%	1.8%	6.0%	5.6%
D/E ratio	0.83	1.18	1.18	0.94	0.9
Shareholders' equity ratio	38.5%	35.0%	33.0%	37.3%	39%
Earnings per share (¥)	13.2	(43.7)	(36.3)	25.6	24.4
Dividends per share (¥)	8.0	5.0	2.0	5.0	6.0
Total assets (¥bn)	1,016.0	874.2	823.1	761.5	760.0
Interest-bearing debt (¥bn)	325.2	361.3	320.3	267.4	260.0
EBITDA (¥bn) *3	127.8	85.3	75.3	105.0	105.0
FCF (¥bn)	(25.5)	(75.9)	47.0	49.4	20.0

*1 ROA= Operating income/Total assets

*2 ROE= Net income/Shareholders' equity

*3 EBITDA = Operating income + Depreciation & amortization

Disclaimer Regarding Forward-Looking Statements and Business Risks

Disclaimer

Any statements in this document, other than those of historical fact, are forward-looking statements about the future performance of Teijin and its Group companies, which are based on management's assumptions and beliefs in light of information currently available, and involve risks and uncertainties. Actual results may differ materially from these forecasts.

Business Risks

The Teijin Group recognizes certain risks as having the potential to affect its operating results and/or financial position. As of the date of this document, these risks included, but were not limited to, the risks listed below.

(1) Market-related risk

The Teijin Group manufactures and sells products, the sales of which may be affected by market conditions, competition with other companies and price fluctuations arising thereof, as well as fluctuations in raw materials prices and fuel costs, and such market factors as fluctuations in foreign exchange and interest rates.

(2) Product quality risk

Teijin's pharmaceuticals and home health care businesses manufacture and sell products that may affect the lives of users. Accordingly, quality issues relating to such products have the potential to negatively affect, among others, the Group's operating results, financial position and public reputation.

(3) R&D-related risk in the pharmaceuticals business

R&D in the pharmaceuticals business is characterized by significant investments of funds and time. Pharmaceuticals discovery research has a high incidence of failure to discover promising drugs. There are also risks that plans to apply for regulatory approval may be abandoned or that approval may be rescinded.

(4) Risks related to overseas operations

The Teijin Group has operations overseas. These operations are vulnerable to the impact of fluctuations in foreign exchange rates, as well as enforcement of new or unexpected changes to existing laws, regulations or tax systems that exert an adverse impact on the Group; economic fluctuations; or social unrest triggered by acts of terror or war.

(5) Risks related to accidents and disasters

In the event of a major natural disaster or unforeseen accident that results in damage to the Teijin Group's production facilities or significantly impedes the Group's supply chain, such developments may have a negative impact on the Group's operating results and/or financial position.

This material is based on the consolidated results for FY11 2Q announced at 11:30 A.M. on November 1, 2011 (local time in Japan).

All product names in this document are registered trademarks.

◆ Consolidated Balance Sheets

(¥bn)	Mar. 31, '10	Jun. 30, '10	Sep. 30, '10	Dec. 31, '10	Mar. 31, '11	Jun. 30, '11	Sep. 30, '11
Total assets	823.1	805.5	776.7	791.9	761.5	782.0	784.5
Current assets	332.7	331.5	326.4	345.0	336.9	358.3	369.4
Fixed assets	490.3	474.1	450.3	446.9	424.6	423.8	415.1
Total liabilities and net assets	823.1	805.5	776.7	791.9	761.5	782.0	784.5
Liabilities	527.8	509.8	482.5	486.3	453.8	468.3	474.2
(Interest-bearing debt)	320.3	329.9	305.9	293.2	267.4	284.6	288.0
Net assets	295.3	295.7	294.3	305.6	307.7	313.8	310.3

Note: For more information, see Teijin's quarterly results report (Consolidated Financial Results for the Second Quarter of FY11).

◆ Consolidated Statements of Income

	(¥bn)	FY10				FY11	
		1Q	2Q	3Q	4Q	1Q	2Q
Net Sales		192.6	207.3	206.3	209.5	189.6	204.0
Cost of sales		140.6	149.5	145.4	150.8	133.9	147.9
Gross profit		52.0	57.8	60.8	58.7	55.7	56.1
SG & A		44.0	45.4	44.9	46.6	44.7	46.5
Operating income		8.1	12.4	15.9	12.2	11.0	9.6
Nonoperating items (net)		(0.3)	0.3	1.0	0.8	1.8	(0.8)
(Balance of financial expenses)		(0.6)	(0.9)	(0.7)	(0.9)	(0.4)	(0.9)
(Equity on gains and losses of unconsolidated subsidiaries and affiliates)		0.9	1.7	2.2	1.5	2.6	1.3
Ordinary income		7.8	12.7	16.9	12.9	12.8	8.9
Extraordinary items(net)		(1.1)	(0.2)	(0.5)	(4.0)	(0.1)	(1.9)
Income before income taxes		6.7	12.5	16.4	8.9	12.7	7.0
Income taxes		2.4	4.5	6.5	2.8	5.9	3.5
Minority interest (net)		0.2	0.5	1.5	0.9	0.5	0.6
Net income		4.0	7.5	8.5	5.2	6.3	2.9

Note: For more information, see Teijin's quarterly results report (Consolidated Financial Results for the Second Quarter of FY11).

◆ Nonoperating items


(¥bn)	FY10 1H	FY11 1H
Interest income	0.2	0.3
Dividend income	0.5	0.5
Equity in earnings of affiliates	2.6	3.9
Other income	0.4	0.5
Nonoperating revenues total	3.7	5.1
Interest expense	2.3	2.1
Foreign exchange loss	0.3	0.8
Other expenses	1.2	1.2
Nonoperating expenses total	3.7	4.1
Nonoperating items total	(0.0)	1.0

◆ Extraordinary items


(¥bn)	FY10 1H	FY11 1H
Gain on sales of investment securities	1.2	-
Gain on sales of subsidiaries and affiliates' stocks	-	0.7
Others	0.3	0.2
Extraordinary income total	1.5	1.0
Loss on disposal and sales of fixed assets	0.2	0.2
Write-down of investment securities	0.2	0.7
Loss on impairment	0.1	1.0
Restructuring costs	1.0	-
Provision for allowance for doubtful accounts	-	0.4
Earthquake-related expenses	-	0.4
Others	1.4	0.3
Extraordinary losses total	2.8	2.9
Extraordinary items total	(1.3)	(2.0)

◆ CAPEX, Depreciation & Amortization, and R&D Expenses

CAPEX /
Depreciation & Amortization




R&D Expenses




◆ Changes in Operating Income by Business Segment

Net Sales


(¥bn)



Operating Income




◆ Dubai Crude Oil Prices



Jan. Apr. Jul. Oct. Jan. Apr. Jul. Oct. Jan. Apr. Jul.

【Source: Teijin estimates based on data published by Platt's】


◆ Benzene Prices




Jan. Apr. Jul. Oct. Jan. Apr. Jul. Oct. Jan. Apr. Jul.

【Source: Teijin estimates based on data published by Dewitt】


◆ Yen/Dollar, Yen/Euro Exchange Rates



◆ Dollar/Euro Exchange Rates




◆ Polyester Fibers Prices, Raw Materials Prices



Jan. Apr. Jul. Oct. Jan. Apr. Jul. Oct. Jan. Apr. Jul.

【Source: Teijin estimates based on data published by PCI】



Jan. Apr. Jul. Oct. Jan. Apr. Jul. Oct. Jan. Apr. Jul.

◆ Sales of Principal Pharmaceuticals

(¥bn)

Product	Indication	FY10					FY11	
		1Q	2Q	3Q	4Q	Annual Total	1Q	2Q
<i>Bonalon*</i>	Osteoporosis	5.2	5.2	5.8	4.8	21.0	5.2	5.2
<i>Onealfa</i>	Osteoporosis	2.9	2.8	3.1	2.6	11.4	2.7	2.7
Osteoporosis total		8.1	8.0	8.9	7.3	32.4	7.9	7.9
<i>Mucosolvan</i>	Expectorant	2.5	2.1	2.9	2.4	10.0	2.4	2.1
<i>Venilon</i>	Severe infection	2.4	2.3	2.4	2.0	9.1	2.3	2.2
<i>Laxoberon</i>	Laxative	1.1	1.1	1.2	1.0	4.4	1.0	1.0
<i>Tricor</i>	Hyperlipidemia	0.4	0.4	0.4	0.5	1.8	0.3	0.4
<i>Bonalfa</i>	Psoriasis	0.4	0.4	0.5	0.3	1.6	0.3	0.3
<i>Alvesco</i>	Asthma	0.3	0.3	0.4	0.3	1.2	0.3	0.3
<i>Spiropent</i>	Bronchodilator	0.3	0.2	0.3	0.2	1.0	0.2	0.2
<i>Synvisc Dispo</i>	Osteoarthritis pain in the knee	-	-	0.2	0.5	0.7	0.4	0.4
<i>Feburic</i>	Hyperuricemia and gout	-	-	-	-	-	0.5	0.0

* *Bonalon*® is the registered trademark of Merck Sharp & Dohme Corp., Whitehouse Station, NJ, U.S.A.

Note: Drugs shown are those with annual sales in excess of ¥1.0 billion

◆ Development Status by Therapeutic Area

(As of September 30, 2011)

	Phase of Clinical Trials				
	Phase I	Phase II	Phase III	Filed	Approved/New Launch
Bone and joint disease	ITM-058			GTH-42V ^{*1} GTH-42J ^{*2} [Bonalon [®]]	
Respiratory disease	NA872ET ^{*3} [Mucosolvan [®]]				BTR-15K [Alvesco [®]] (New indication: asthma in children)
Cardio-vascular and metabolic disease		ITM-077 NTC-801		ITM-014 ^{*4}	TMX-67 [Feburic [®]]
Other		GGs ^{*5} [Venilon [®]] (New indication for microscopic polyangiitis)	GGs [Venilon [®]] (New indication for multiple sclerosis)	TV-02H [Bonalfa [®] Ointment] (PRC)	

*1 Teijin filed for approval to manufacture and market GTH-42V in Japan in February 2011.

*2 Teijin filed for approval to manufacture and market GTH-42J in Japan in August 2011.

*3 Phase I clinical trials for NA872ET began in September 2011.

*4 Teijin filed for approval to manufacture and market ITM-014 in Japan in September 2011.

*5 Teijin commenced clinical testing of GGs (Venilon[®]) for microscopic polyangiitis, a new indication.

◆ Status of New Products

(As of September 30, 2011)

Brand name (Generic name)	Target disease	Medical properties/characteristics	Dosage form	Remarks
Synvisc Dispo 2ml (Sodium hyaluronate cross-linked polymer, cross-linked with vinyl sulfone)	Pain in osteoarthritis (OA) of the knee	Treatment for pain associated with OA of the knee. Because molecular weight of sodium hyaluronate closely matches that of healthy synovial fluid, direct injection into the knee causes a temporary increase in synovial fluid viscosity, improving resistance to joint damage and relieving pain. Doses are smaller and fewer injections are needed to achieve extended pain relief, compared with other viscosupplements.	Injection	Licensed in from Genzyme Corporation (U.S.A.) Commenced sales in Japan on December 14, 2010
Feburic (febuxostat)	Gout and hyperuricemia	A novel non-purine drug that inhibits synthesis of uric acid; taken once daily, it reduces serum uric acid levels to the target level and keeps it low; no adjustment of dosage is required for patients with mild to moderate renal impairment, thereby offering hope to a significantly broader group of patients.	Oral	Developed in-house Commenced sales in Japan on May 17, 2011
Alvesco 100µg Inhaler 56 Puff (ciclesonide)	Asthma in children	A new indication for Alvesco, an inhaled steroid for treating asthma already on the market, for children; this is the first drug of its kind in Japan that is taken once daily; equally or more efficacious than other inhaled steroids, and less likely to cause either systemic or localized side effects.	Inhaled	Licensed in from Nycomed Group (Switzerland) Approved for new indication (asthma in children) on January 21, 2011 Commenced sales in Japan on April 7, 2011

◆ Newly Developed Pharmaceutical Candidates

【 Filed 】

(As of September 30, 2011)

Code No. (Generic name)	Target disease	Medical properties/characteristics	Dosage form	Remarks
TV-02H (tacalcitol monohydrate)	Psoriasis vulgaris	Licensing-out of <i>Bonalfa</i> high ointment 20 μ g/g to China; This product will offer an additional treatment option for psoriasis in China. Although two strengths (2 μ g/g and 20 μ g/g) of <i>Bonalfa</i> ointment are available in Japan, only <i>Bonalfa</i> ointment 2 μ g/g is available in China at present.	Topical ointment	Filed with PRC's State Food and Drug Administration in September 2010 (Supplemental NDA to <i>Bonalfa</i> ointment 2 μ g/g)
GTH-42V (alendronate sodium hydrate)	Osteoporosis	Intravenous form of <i>Bonalon</i> , currently sold as an osteoporosis drug; holds promise as an alternative prescription in cases where patients are unable to take oral medications or where patient noncompliance is an issue; also promising because less likely than oral drugs to cause side effects in the upper gastrointestinal tract.	Injection	Licensed in from Merck & Co., Inc. (USA) Filed in Japan in February 2011.
GTH-42J (alendronate sodium hydrate)	Osteoporosis	Oral jelly formulation of <i>Bonalon</i> (alendronate sodium hydrate), currently sold as an osteoporosis drug; intended as the world's first jelly-form osteoporosis treatment; offers promise as an alternative for osteoporosis patients who dislike taking pills because it is easy to swallow and moderately firm, so holds shape; also promising because it is easily managed by elderly individuals.	Oral jelly	Licensed in from Merck & Co., Inc. (USA)
ITM-014 (Lanreotide acetate)	Acromegaly	Suppresses the excessive secretion of growth hormones associated with acromegaly; pharmaceutical formulation facilitates sustained release and extended pharmaceutical action, while prefilled syringe format makes it more convenient than existing acromegaly drugs and thus more conducive to patient compliance.	Injection	Licensed in from Ipsen Pharma SAS (France)

【Phase III】

Code No. (Generic name)	Target disease	Medical properties/characteristics	Dosage form	Remarks
GGs (freeze-dried sulfonated human immunoglobulin)	Multiple sclerosis	Elicits an immune response that lowers the frequency of neurological manifestations of multiple sclerosis; holds promise as the first-choice alternative in cases where side effects and/or patient noncompliance mean existing drugs are unviable.	Injection	Developing jointly with Kaketsuken (New indication)

【Phase II】

Code No. (Generic name)	Target disease	Medical properties/characteristics	Dosage form	Remarks
ITM-077 (Taspoglutide)	Type II diabetes	Consists glycemic control with low risk of hypoglycemia, which stimulating glucose-dependent insulin secretion; Has body weight loss effect; once-weekly dosage is possible, enhancing convenience; Also expecting it protects and promotes regeneration of pancreatic beta cells, which secrete insulin.	Injection	Licensed in from Ipsen Pharma SAS (France)
NTC-801	Atrial fibrillation and flutter	Promising atrial selective anti-arrhythmic drug for the treatment and prevention of atrial fibrillation and flutter; expecting that it does not cause ventricular side effects, such as arrhythmogenic or negative inotropic action, a problem with existing anti-arrhythmic drugs.	Oral	Developing jointly with Nissan Chemical Industries, Ltd.
GGs (freeze-dried sulfonated human immunoglobulin)	Microscopic polyangiitis	Drug's anti-inflammatory and immunoregulatory actions mitigate autoimmune vasculitis; also promising as a treatment for mononeuritis multiplex, a neuropathic disorder that is not alleviated by standard therapies.	Injection	Developing jointly with Kaketsuken (New indication)

【Phase I】

Code No. (Generic name)	Target disease	Medical properties/characteristics	Dosage form	Remarks
ITM-058	Osteoporosis	Promising for the treatment of osteoporosis due to potency in promoting bone formation, resulting in a rapid increase in bone density and reduction in the risk of fracture. Superior to existing PTH derived drugs in its ability to increase bone density and its safety (minimal risk of hypercalcemia).	Injection	Licensed in from Ipsen Pharma SAS (France)
NA872ET	Expectorant	Small, sustained-release tablet-form version of <i>Mucosolvan</i> (ambroxol hydrochloride) that is smaller than <i>Mucosolvan</i> L Capsule and thus easier to take. This version is promising because it allows easier apportioning of single doses	Oral	Licensed in from Boehringer Ingelheim GmbH (Germany)

TEIJIN

Human Chemistry, Human Solutions

Human Chemistry, Human Solutions

The promise of the Teijin brand is summed up in the resonant statement: "Human Chemistry, Human Solutions".

Our promise is to continue to develop chemical technologies that are friendly to both people and the global environment. It is to keep providing solutions that deliver the real value that society and our customers expect.

We will certainly keep this promise. Constantly working to enhance the Quality of Life –our very reason for being as a company– the Teijin Group will continue to win the trust of society and our customers.